Oncolytic adenovirus in combination with PD-L1-targeted radioimmunotherapy exerts synergistic antitumor effect against pancreatic cancer

BACKGROUND: To date, no radioimmunotherapy (RIT) regimen has been approved by US Food and Drug Administration for the treatment of pancreatic cancers. Highly desmoplastic and immune-desert phenotypes of pancreatic cancer remain two major hurdles that attenuate the efficacy of conventional treatment (radiotherapy and chemotherapy) and immunotherapeutic (immune checkpoint inhibitors and chimeric antigen receptor T cells). METHOD: Lu-aPD-L1)). RESULTS: T cells over the respective monotherapy. CONCLUSION: Lu-aPD-L1 in a multifaceted manner to elicit synergistic antitumor immune response against desmoplastic and poorly immunogenic pancreatic tumors.

Authors

Institutions

Publication Details

Journal
Journal for ImmunoTherapy of Cancer
Published
2026-04-01
DOI
https://doi.org/10.1136/jitc-2025-014508
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Oncolytic adenovirus in combination with PD-L1-targeted radioimmunotherapy exerts synergistic antitumor effect against pancreatic cancer

Jeongwon Lee, Jeemin Seo, Hyeju Jeong, Ji Soo Yi et al.
Journal for ImmunoTherapy of Cancer
RNA Interference and Gene Delivery
article

Oncolytic adenovirus in combination with PD-L1-targeted radioimmunotherapy exerts synergistic antitumor effect against pancreatic cancer

Jeongwon Lee, Jeemin Seo, Hyeju Jeong, Ji Soo Yi, Jinwoo Hong, Chae‐Ok Yun, In-Wook Kim, Javeria Zaheer, Joycie Shanmugiah, Ju Hee Kim, Arum R. Yoon, Seungyoun Kim, Hyeongi Kim
article en

Abstract

BACKGROUND: To date, no radioimmunotherapy (RIT) regimen has been approved by US Food and Drug Administration for the treatment of pancreatic cancers. Highly desmoplastic and immune-desert phenotypes of pancreatic cancer remain two major hurdles that attenuate the efficacy of conventional treatment (radiotherapy and chemotherapy) and immunotherapeutic (immune checkpoint inhibitors and chimeric antigen receptor T cells). METHOD: Lu-aPD-L1)). RESULTS: T cells over the respective monotherapy. CONCLUSION: Lu-aPD-L1 in a multifaceted manner to elicit synergistic antitumor immune response against desmoplastic and poorly immunogenic pancreatic tumors.

Journal for ImmunoTherapy of CancerVol. 14(4)
Korea Institute of Radiological and Medical Sciences (KR), Hanyang University (KR), Korea Institute of Science and Technology (KR), Korea University of Science and Technology (KR), Anyang University (KR)
National Research Foundation, Ministry of Food and Drug Safety, Korea Health Industry Development Institute, Korea Basic Science Institute, National Research Foundation of Korea, Ministry of Science and ICT, South Korea
Good health and well-being
Openalex Percentile: Top 26%
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.